Trials / Withdrawn
WithdrawnNCT05496192
A Study of Nivolumab Intravenous (IV) to Subcutaneous (SC) Switch in Adjuvant Melanoma and Bladder Cancer
A Phase II Study of Adjuvant Nivolumab Switch From Intravenous (IV) to Subcutaneous (SC) Use in Participants With Resected Stage III or Stage IV Melanoma or High Risk Invasive Urothelial Carcinoma Originating in the Bladder
- Status
- Withdrawn
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the switch from Nivolumab Intravenous (IV) infusions to Nivolumab Subcutaneous (SC) administration in participants with resected Stage IIIA/B/C/D or Stage IV melanoma or resected invasive Urothelial Carcinoma (UC) originating in the bladder who have high risk of recurrence.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Nivolumab/rHuPH20 | Specified dose on specified days |
| DRUG | Nivolumab | Specified dose on specified days |
Timeline
- Start date
- 2023-05-31
- Primary completion
- 2024-06-24
- Completion
- 2026-06-24
- First posted
- 2022-08-11
- Last updated
- 2023-04-14
Locations
3 sites across 2 countries: Germany, Spain
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05496192. Inclusion in this directory is not an endorsement.